plus

Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema

October 28, 2025 16:05 ET  | Source: Tactile Systems Technology, Inc. MINNEAPOLIS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tactile Systems…

1 month ago

DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line

CHONGQING, China, Oct. 22, 2025 /PRNewswire/ -- On October 22, 2025, at the Chongqing SERES Shuangfu Plant, DFSK's first overseas new…

1 month ago

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

2 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

October 19, 2025 08:00 ET  | Source: Replimune, Inc. WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…

2 months ago

Sandstone Easydrip Plus Pen Needles Debut in Turkey — PatentProtected Hexagonal Hub for Comfort and Control

Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip; ISO 13485 & CE certified; launched by a leading…

2 months ago

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

2 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

2 months ago

RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,…

3 months ago

Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification, Strengthening Global Leadership in Sustainable and Traceable Supply Chains

KOLKATA, India, Aug. 29, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd (HSCL), a global leader in speciality chemicals and advanced…

3 months ago

Plus Therapeutics Reports Stockholders Equityin Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

August 15, 2025 07:30 ET  | Source: Plus Therapeutics Inc. HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc.…

4 months ago